Reporting of Patient-Reported Outcomes in Randomized Trials The CONSORT PRO Extension

被引:978
作者
Calvert, Melanie [1 ]
Blazeby, Jane [2 ]
Altman, Douglas G. [3 ]
Revicki, Dennis A. [4 ]
Moher, David [5 ]
Brundage, Michael D. [6 ]
机构
[1] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England
[2] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England
[3] Univ Oxford, Ctr Stat Med, Oxford OX1 2JD, England
[4] United BioSource Corp, Outcomes Res, Bethesda, MD USA
[5] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
[6] Queens Univ, Canc Res Inst, Kingston, ON, Canada
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2013年 / 309卷 / 08期
基金
英国医学研究理事会; 加拿大健康研究院;
关键词
QUALITY-OF-LIFE; LOW-BACK-PAIN; PHASE-III; EUROPEAN-ORGANIZATION; CLINICAL-TRIAL; MISSING DATA; CANCER; THERAPY; GEMCITABINE; PACLITAXEL;
D O I
10.1001/jama.2013.879
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The CONSORT (Consolidated Standards of Reporting Trials) Statement aims to improve the reporting of randomized controlled trials (RCTs); however, it lacks guidance on the reporting of patient-reported outcomes (PROs), which are often inadequately reported in trials, thus limiting the value of these data. In this article, we describe the development of the CONSORT PRO extension based on the methodological framework for guideline development proposed by the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network. Five CONSORT PRO checklist items are recommended for RCTs in which PROs are primary or important secondary end points. These recommendations urge that the PROs be identified as a primary or secondary outcome in the abstract, that a description of the hypothesis of the PROs and relevant domains be provided (ie, if a multidimensional PRO tool has been used), that evidence of the PRO instrument's validity and reliability be provided or cited, that the statistical approaches for dealing with missing data be explicitly stated, and that PRO-specific limitations of study findings and generalizability of results to other populations and clinical practice be discussed. Examples and an updated CONSORT flow diagram with PRO items are provided. It is recommended that the CONSORT PRO guidance supplement the standard CONSORT guidelines for reporting RCTs with PROs as primary or secondary outcomes. Improved reporting of PRO data should facilitate robust interpretation of the results from RCTs and inform patient care. JAMA. 2013;309(8):814-822
引用
收藏
页码:814 / 822
页数:9
相关论文
共 37 条
[31]  
Sculpher M J, 2004, Health Technol Assess, V8, piii
[32]  
Sculpher MJ, 2004, HEALTH TECHNOL ASSES, V8, P1
[33]   Assessing meaningful change in quality of life over time: A users' guide for clinicians [J].
Sprangers, MAG ;
Moinpour, CM ;
Moynihan, TJ ;
Patrick, DL ;
Revicki, DA .
MAYO CLINIC PROCEEDINGS, 2002, 77 (06) :561-571
[34]   Sifting the evidence - what's wrong with significance tests? [J].
Sterne, JAC ;
Smith, GD .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7280) :226-+
[35]   Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals [J].
Turner, Lucy ;
Shamseer, Larissa ;
Altman, Douglas G. ;
Weeks, Laura ;
Peters, Jodi ;
Kober, Thilo ;
Dias, Sofia ;
Schulz, Kenneth F. ;
Plint, Amy C. ;
Moher, David .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (11)
[36]   Intensive group training protocol versus guideline physiotherapy for patients with chronic low back pain: a randomised controlled trial [J].
van der Roer, Nicole ;
van Tulder, Maurits ;
Barendse, Johanna ;
Knol, Dirk ;
van Mechelen, Willem ;
de Vet, Henrica .
EUROPEAN SPINE JOURNAL, 2008, 17 (09) :1193-1200
[37]   Health related quality of life after combined hormone replacement therapy: randomised controlled trial [J].
Welton, Amanda J. ;
Vickers, Madge R. ;
Kim, Joseph ;
Ford, Deborah ;
Lawton, Beverley A. ;
MacLennan, Alastair H. ;
Meredith, Sarah K. ;
Martin, Jeannett ;
Meade, Tom W. .
BRITISH MEDICAL JOURNAL, 2008, 337 (7669) :550-553